British American Tobacco: Clearing the Air
What this covers
Evan Tindell walks Matt through British American Tobacco in two halves: where the company came from, and what its numbers look like now. The history starts with the 1880 Bonsack machine, which lifted cigarette output from a couple hundred a day to 70,000. It moves to Buck Duke and the American Tobacco Company, then to BAT's 1901 founding, when Duke's firm and the 13 British companies that became Imperial Tobacco split home markets and sold abroad jointly. Later chapters cover Camel, Marlboro's switch from a women's brand to a cowboy brand, the 1998 Master Settlement Agreement, and BAT's route to the number two US spot through Brown & Williamson and R.J. Reynolds.
The financial section is concrete. US volumes fall 2 to 4 percent a year while price increases keep revenue flat, gross margin has climbed from 78 to about 83 percent, and GBP 9.2 billion of operating cash flow needs only GBP 500 million of capital spending. Advertising bans freeze brand rankings, which Evan treats as a benefit to the leaders. He also argues that regulation entrenches incumbents, a point Matt labels regulatory capture.
The contested material concerns newer products. It covers how nicotine pouches differ from older snus, the three regulatory tiers of reduced-risk products, and why vape market data is unreliable when roughly half the volume is disposables. Altria's figures suggest total US nicotine volume is growing about 1 percent a year, and Japan's heated-tobacco shift is offered as a sign the market can expand. Evan even floats nicotine becoming something like caffeine. The menthol ban gets its own treatment: menthol is about a quarter of US revenue, and he sizes the hit at 10 to 15 percent of profits.
Evan Tindell argues British American Tobacco is a stable, cash-generative, under-appreciated value stock whose traditional cigarette decline is offset by price increases and whose next-generation nicotine products could turn the melting ice cube into a growing business, while a US menthol ban is the main risk.
- Price increases have offset low single-digit volume declines, keeping US traditional revenue flat
- Margins and cash conversion are stable, so a roughly 10% dividend yield at about 6x free cash flow limits downside
- Next-generation products like ZYN and VELO may expand total nicotine demand, and a US menthol ban is the key regulatory risk
Regulation entrenches incumbent tobacco firms, which hold dominant market positions.
- Altria is the number one US tobacco company and BAT the strong number two in combustibles, while Philip Morris International's IQOS is the largest next-generation brand and has recently passed Marlboro as PMI's largest brand.
“Altria is the #1 U.S. company, and then a strong #2 is BAT. And Philip Morris is the biggest competitor elsewhere.”
- Regulation such as advertising bans and FDA approval requirements has entrenched existing tobacco companies and benefited them, a dynamic Evan says people do not fully understand, which Matt characterizes as regulatory capture.
“I don't know if people really understand how much it entrenched the existing tobacco companies and kind of benefited them, but it's just kind of part of the deal with this level of regulation.”
Tobacco's colonial origins tied the US industry to the slave trade.
- John Rolfe planted the first tobacco in Jamestown in 1612, and tobacco turned a colony where only 40 people survived one year into a financially sustainable enterprise, tying US tobacco to the slave trade over the following centuries.
“John Rolfe, who planted the first tobacco plant in Jamestown in 1612. ... with tobacco, it was turned into an actual financially sustainable colony”